Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...

For now, sales of Lilly’s injectable drugs with tirzepatide are driving the company’s growth. In the first quarter of 2025, Mounjaro had $3.84 billion in revenue and Zepbound $2.31 billion ...

Talk to your healthcare provider about how you can take part in this registry, or you may contact Lilly at 1-800-LillyRx (1-800-545-5979). Zepbound ... between our sales teams and authors ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to halt the sale and production of off-brand products that many patients in ...

Novo Nordisk has been ceding market share to Eli Lilly, even though Zepbound's dollar sales still trail Wegovy ... the body and doesn't require dietary restrictions like oral semaglutide does ...

Novo Nordisk said it had been able to ease some of the restrictions ... Earlier this week, Lilly raised its earnings forecasts as well, on the back of rising sales of Zepbound and diabetes therapy ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to halt the sale ... Zepbound and Mounjaro from competitor Eli Lilly.

The supply of GLP-1 drugs for weight loss and diabetes treatment was expected to tighten this week with a federal deadline to halt the sale ... Zepbound and Mounjaro from competitor Eli Lilly.